{"DataElement":{"publicId":"7307904","version":"1","preferredName":"Disease Status NCCN ALL Response Criterion Lymphomatous Extramedullary Disease Type","preferredDefinition":"A description of the NCCN ALL disease response criteria for lymphomatous extramedullary disease.","longName":"DIS_NCCN_ALL_RSP_CRT_LED_TY","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"2512861","version":"1","preferredName":"Disease or Disorder Status","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time.","longName":"2404658v1.0:2320064v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320064","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037B-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B898979-184A-3A90-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7307895","version":"1","preferredName":"NCCN ALL Response Criterion Lymphomatous Extramedullary Disease Type","preferredDefinition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology._Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison._A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._Outside of, or unrelated to, any medulla, especially the medulla oblongata._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Something distinguishable as an identifiable class based on common qualities.","longName":"NCCN_ALL_RSP_CRT_LED_TY","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A44AFE-8000-316C-E053-4EBD850A80E9","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Relapse","ValueMeaning":{"publicId":"7307896","version":"1","preferredName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Relapse","longName":"7307896","preferredDefinition":"Recurrence of mediastinal enlargement after achieving CR. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Relapse","conceptCode":"C172180","definition":"Recurrence of mediastinal enlargement after achieving CR. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A44AFE-800C-316C-E053-4EBD850A80E9","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A44AFE-8025-316C-E053-4EBD850A80E9","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"No Response (NR)","valueDescription":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease No Response","ValueMeaning":{"publicId":"7307897","version":"1","preferredName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease No Response","longName":"7307897","preferredDefinition":"Failure to qualify for partial response or progressive disease. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease No Response","conceptCode":"C172179","definition":"Failure to qualify for partial response or progressive disease. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A44AFE-8031-316C-E053-4EBD850A80E9","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A44AFE-804A-316C-E053-4EBD850A80E9","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"PD","valueDescription":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Progressive Disease","ValueMeaning":{"publicId":"7307898","version":"1","preferredName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Progressive Disease","longName":"7307898","preferredDefinition":"Greater than 25 percent increase in the SPD of patients with mediastinal enlargement. For patients with previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Progressive Disease","conceptCode":"C172178","definition":"Greater than 25 percent increase in the SPD of patients with mediastinal enlargement. For patients with previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A44AFE-8056-316C-E053-4EBD850A80E9","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A44AFE-806F-316C-E053-4EBD850A80E9","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"PR","valueDescription":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Partial Remission","ValueMeaning":{"publicId":"7307899","version":"1","preferredName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Partial Remission","longName":"7307899","preferredDefinition":"Greater than 50 percent disease in the sum of product of greatest perpendicular diameters (SPD) of the mediastinal enlargement for patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Partial Remission","conceptCode":"C172177","definition":"Greater than 50 percent disease in the sum of product of greatest perpendicular diameters (SPD) of the mediastinal enlargement for patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A44AFE-807B-316C-E053-4EBD850A80E9","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A44AFE-8094-316C-E053-4EBD850A80E9","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"CR","valueDescription":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Complete Remission","ValueMeaning":{"publicId":"7307900","version":"1","preferredName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Complete Remission","longName":"7307900","preferredDefinition":"Complete resolution of lymphomatous enlargement by CT. For patients with a previous positive PET scan, a post-treatment residual mass of any size is considered a CR as long as it is PET negative. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Complete Remission","conceptCode":"C172176","definition":"Complete resolution of lymphomatous enlargement by CT. For patients with a previous positive PET scan, a post-treatment residual mass of any size is considered a CR as long as it is PET negative. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A44AFE-80A0-316C-E053-4EBD850A80E9","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A44AFE-80B9-316C-E053-4EBD850A80E9","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7307894","version":"1","preferredName":"National Comprehensive Cancer Network Acute Lymphoblastic Leukemia Disease Response Criterion Lymphoma Extramedullary Disease or Disorder Type","preferredDefinition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.:Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.:That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.:A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.:Outside of, or unrelated to, any medulla, especially the medulla oblongata.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Something distinguishable as an identifiable class based on common qualities.","longName":"7307894v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Comprehensive Cancer Network","conceptCode":"C39471","definition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Criterion","conceptCode":"C25466","definition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Extramedullary","conceptCode":"C25503","definition":"Outside of, or unrelated to, any medulla, especially the medulla oblongata.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A44AFE-7FDB-316C-E053-4EBD850A80E9","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A44AFE-7FEC-316C-E053-4EBD850A80E9","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"KUMMEROA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Acute Lymphoblastic Leukemia","type":"Preferred Question Text","description":"Acute Lymphoblastic Leukemia Response Criteria for Lymphomatous Extramedullary Disease","url":null,"context":"DCI"}],"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A45CC5-6A24-316A-E053-4EBD850A5BCD","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"KUMMEROA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}